Syndax has submitted a supplemental New Drug Application/sNDA seeking approval for revumenib to treat R/R mNPM1 AML. The US ...
A new anti-money laundering rule requires title and settlement companies to collect information on certain non-financed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback